TY - CHAP M1 - Book, Section TI - Myeloproliferative Neoplasms A1 - Rowe, Julie H. A1 - Gonzalez, Anneliese O. A1 - Jafri, Syed H. A1 - Cen, Putao A1 - Kanaan, Zeyad A1 - Amato, Robert J. A1 - Rios, Adan A1 - El-Osta, Hazem A1 - Mohlere, Virginia Y1 - 2019 N1 - T2 - Hematology-Oncology Clinical Questions AB - Table Graphic Jump Location|Download (.pdf)|PrintKey conceptMPNs include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). They are characterized by being Philadelphia chromosome–negative.Clinical scenarioA 56-year-old woman is admitted to the emergency room with a severe case of pharyngitis. In addition to her symptom of pharyngitis, a peripheral blood count reveals 1 × 106 platelets/dL. She is told she has ET. Blood is drawn for determination of JAK2 mutations.Action itemsSchedule bone marrow aspiration and biopsyObtain blood for determination of JAK2 mutationsStart patient on acetylsalicylic acid (low-dose aspirin)DiscussionMPNs are a group of heterogeneous disorders that are characterized by a risk of transformation to acute myeloid leukemia and are collectively Philadelphia chromosome–negative. The profile varies for each type, but indications often include constitutional symptoms, fatigue, pruritus, weight loss, splenomegaly, and laboratory abnormalities such as erythrocytosis, thrombocytosis, and leukocytosis. Patients with MF have worse survival than patients with PV and ET. MPNs are diagnosed by identifying driver mutations such as JAK2, CALR, and MPL mutations.1PearlMPNs are not associated with chromosomal abnormalitiesReferencesMesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer 2016;16:167. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - hemonc.mhmedical.com/content.aspx?aid=1162981513 ER -